ARGX and 0QW0 Related Headlines

Apr 16, 2024 01:00AM argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

Mar 27, 2024 02:00AM argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

Feb 20, 2024 01:00AM argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Jan 18, 2024 01:00AM argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

Jan 8, 2024 01:00AM argenx Highlights 2024 Strategic Priorities

Dec 20, 2023 01:00AM argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Nov 16, 2023 07:41AM argenx (ARGX) Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

Nov 16, 2023 07:40AM argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

Sep 21, 2023 01:00AM argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

Jun 30, 2023 09:39AM argenx (ARGX) and Zai Lab (ZLAB) Announce FDA Approval of VYVGART

Jun 30, 2023 09:39AM argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Jun 30, 2023 09:25AM Zai Lab Limited (ZLAB) and argenx Announce Approval of VYVGART for Generalized Myasthenia Gravis in China

Jun 30, 2023 09:22AM Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Jun 20, 2023 06:12PM argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis

Jun 20, 2023 01:00AM argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

May 2, 2023 01:00AM argenx to Present at BofA Securities 2023 Health Care Conference

Apr 27, 2023 01:00AM argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023

ARGX and 0QW0 Related Press Releases

Apr 16, 2024 01:00AM argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

Mar 27, 2024 02:00AM argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

Feb 20, 2024 01:00AM argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Jan 18, 2024 01:00AM argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

Jan 8, 2024 01:00AM argenx Highlights 2024 Strategic Priorities

Dec 20, 2023 01:00AM argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Nov 16, 2023 07:40AM argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

Sep 21, 2023 01:00AM argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

Jun 30, 2023 09:39AM argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Jun 30, 2023 09:22AM Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Jun 20, 2023 06:12PM argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis

Jun 20, 2023 01:00AM argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

May 2, 2023 01:00AM argenx to Present at BofA Securities 2023 Health Care Conference

Apr 27, 2023 01:00AM argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023

ARGX and 0QW0 Related SEC Filings

Apr 16, 2024 06:06AM Form 6-K ARGENX SE For: Apr 16

Mar 27, 2024 06:15AM Form 6-K ARGENX SE For: Mar 27

Mar 27, 2024 06:08AM Form 6-K ARGENX SE For: Mar 27

Mar 26, 2024 06:05AM Form 6-K ARGENX SE For: Mar 26

Mar 21, 2024 06:24AM Form 20-F ARGENX SE For: Dec 31

Mar 21, 2024 06:13AM Form 6-K ARGENX SE For: Mar 21

Mar 8, 2024 06:05AM Form 6-K ARGENX SE For: Mar 07

Feb 29, 2024 04:05PM Form 6-K ARGENX SE For: Feb 29

Feb 20, 2024 06:07AM Form 6-K ARGENX SE For: Feb 20

Feb 14, 2024 10:05AM Form SC 13G/A ARGENX SE Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Feb 12, 2024 07:01AM Form SC 13G ARGENX SE Filed by: Artisan Partners Limited Partnership

Feb 9, 2024 08:37AM Form SC 13G/A ARGENX SE Filed by: FMR LLC

Feb 1, 2024 01:05PM Form SC 13G/A ARGENX SE Filed by: BlackRock Inc.

Jan 18, 2024 06:11AM Form 6-K ARGENX SE For: Jan 18

Jan 8, 2024 06:07AM Form 6-K ARGENX SE For: Jan 08

Dec 20, 2023 06:01AM Form 6-K ARGENX SE For: Dec 20

Nov 28, 2023 06:14AM Form 6-K ARGENX SE For: Nov 28

Nov 17, 2023 06:04AM Form 6-K ARGENX SE For: Nov 17

Nov 1, 2023 04:02PM Form 6-K ARGENX SE For: Nov 01

Oct 31, 2023 09:15AM Form 6-K ARGENX SE For: Oct 31

Sep 27, 2023 04:42PM Form S-8 ARGENX SE

Sep 21, 2023 08:39AM Form 6-K ARGENX SE For: Sep 20

Jul 27, 2023 06:03AM Form 6-K ARGENX SE For: Jun 30

Jul 21, 2023 06:01AM Form 6-K ARGENX SE For: Jul 18

Jul 20, 2023 04:52PM Form 424B5 ARGENX SE

Jul 17, 2023 04:42PM Form 424B5 ARGENX SE

Jul 17, 2023 07:57AM Form 6-K ARGENX SE For: Jul 17

Jun 30, 2023 04:02PM Form 6-K ARGENX SE For: Jun 29

Jun 21, 2023 08:53AM Form 6-K ARGENX SE For: Jun 21

May 5, 2023 08:06AM Form 6-K ARGENX SE For: May 05

May 5, 2023 08:04AM Form 6-K ARGENX SE For: May 05